Azienda Socio Sanitaria Locale N. 8 Di Cagliari
- Address
- lock Available on a paid plan
Azienda Socio Sanitaria Locale N. 8 Di Cagliari - Advanced Neurological and Hematological Research
Azienda Socio Sanitaria Locale N. 8 Di Cagliari is a distinguished clinical research institution with extensive expertise in complex neurological disorders and hematological conditions. The center demonstrates particular strength in multiple sclerosis research, participating in cutting-edge trials investigating novel therapeutic approaches including BTK inhibitors and neurofilament-targeted treatments across various disease subtypes.
- Multiple Sclerosis spectrum disorders, including primary progressive, radiologically isolated syndrome, and novel biomarker-based interventions
- Thalassemia management in both transfusion-dependent and non-transfusion-dependent populations
- Pediatric neuropsychiatric conditions and migraine disorders across different age groups
- Hematologic malignancies with focus on multiple myeloma treatment protocols and autologous transplantation
The center's research portfolio reflects a commitment to addressing rare and complex conditions, including pediatric acute-onset neuropsychiatric syndrome (PANS), Langerhans Cell Histiocytosis, and cardiovascular complications such as atrial fibrillation in high-risk populations. With participation in international collaborative protocols and phase 2-3 clinical trials, the institution contributes significantly to advancing evidence-based treatments for both pediatric and adult patient populations across multiple therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1H. Lundbeck A/S2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1H. Lundbeck A/S2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Socio Sanitaria Locale N. 8 Di Cagliari
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Non-inferiority Study Comparing Subcutaneous versus Intravenous Administration of Frexalimab in Adults with Multiple Sclerosis | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Eptinezumab | 2 | Unknown | 2022-11-08 | 2023-03-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.